Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2018 10/16/2018 10/17/2018 10/18/2018 10/19/2018 Date
61.79(c) 66.16(c) 66.04(c) 64.14(c) 63.28(c) Last
921 080 690 195 454 704 599 077 784 534 Volume
-4.56% +7.07% -0.18% -2.88% -1.34% Change
More quotes
Financials (USD)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
Sales 2019 106 M
EBIT 2019 -367 M
Net income 2019 -364 M
Finance 2019 266 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 52,0x
EV / Sales2019 27,4x
Capitalization 3 176 M
More Financials
Company
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases.Its product includes Mepsevii and Crysvita.The company was founded... 
More about the company
Surperformance© ratings of Ultragenyx Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on ULTRAGENYX PHARMACEUTICAL
10/19ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Brazil for the Tre..
AQ
10/18Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazi..
GL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/19ULTRAGENYX PHARMACEUTICAL : appoints Dr. Wladimir Hogenhuis as COO
AQ
09/17ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers, Fina..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/18Want automatic email alerts for $ACSF $SC $CELP $RARE $DRNA? Subscribe to Mar.. 
10/18Anyone who's been long since around the time of the IPO w/ $RARE $RVNC $ATRA .. 
10/16Ultragenyx Pharmaceutical $RARE Downgraded to Buy at ValuEngine  
10/15DOWNSIDE MOMENTUM ALERT: $RARE ULTRAGENYX PHARMACEUTICALS INC ? TradeIdeas vi.. 
10/13Ultragenyx Pharmaceutical $RARE Downgraded by ValuEngine  
More tweets
Qtime:80
News from SeekingAlpha
09/27Ultragenyx's DTX301 shows positive effect in OTC study 
09/17Ultragenyx appoints Dr. Wladimir Hogenhuis as COO 
09/10Premarket analyst action - healthcare 
09/05Gene therapy players under pressure 
08/29YOUR DAILY PHARMA SCOOP : ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozemp.. 
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 219
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222